{
  "id": "fda_guidance_chunk_0160",
  "title": "Introduction - Part 160",
  "text": "endpoint. For example, in some oncology trials, progression-free survival is selected as the primary endpoint, and overall survival is selected as the secondary endpoint because an effect of treatment on disease progression is clinically important and may be more readily demonstrable, may be detected earlier, and may often be larger because the observed effect on overall survival can be impacted by subsequent treatment post progression. B. Type II Error Rate and Sample Size FDA is also concerned with the risk of making a Type II error, which is failing to show an effect of a drug where there actually is one. The study power is the probability that the study will be successful if a treatment effect of a specified size is in fact present. The desired power is an important factor in determining the sample size, especially for the primary endpoints. The sample size of a study is generally chosen to provide a reasonably high power to show a treatment effect if an effect of a specified size on the primary endpoint(s) is in fact present. The sample size calculation may need to account for the statistical adjustments to control the Type I error rate for multiplicity. For example, if a lower ÔÅ° level is used for a study endpoint, then the sample size should be adjusted to provide desired statistical power for this endpoint. Using two or more endpoints for which demonstration of an effect on each is recommended to support regulatory approval (called co-primary endpoints; see section III.C.1. below) will increase the Type II error rate and decrease study power. For example, assume two endpoints have the same effect size and the study sample size is selected to provide 80% power to show success on each of these two endpoints. If the endpoints are independent, the power to show success on both will be approximately 64% (0.8 x 0.8); i.e., the likelihood of the study failing to support a conclusion of a favorable drug effect when such an effect existed (the Type II error rate) would be 36%. To maintain desired study power, a larger sample size is recommended, and the individual endpoints could be powered at approximately 90% to ensure the probability of success is at least 80%. The calculation would be different if the endpoints were highly positively correlated",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 213696,
  "end_pos": 215232,
  "tokens": 512,
  "tags": [
    "safety",
    "efficacy",
    "design",
    "statistical",
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.687Z"
}